Research map: A comparison of efficacy and prognosis between RC48 combined immunotherapy and gemcitabine–cisplatin combined immunotherapy in bladder-preserving multimodal therapy for muscle-invasive bladder cancer

Back to the article

Papers in this map

  1. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial · Thomas B. Powles · 2017 · 1444 citations · Cited by this paper
  2. Machine learning–based prediction of Clavien–Dindo ≥ II complications after ureteroscopy · 2026 · Related
  3. Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) · Amylou Constance Dueck · 2015 · 1045 citations · Cited by this paper
  4. Micropapillary variant of upper tract urothelial carcinoma: a SEER-based propensity score–matched analysis of clinicopathological features and survival outcomes · 2026 · Related
  5. Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH Experience · Jason Alexander Efstathiou · 2011 · 435 citations · Cited by this paper
  6. Kidney transplantation outcomes in recipients with end-stage kidney disease due to primary vesicoureteral reflux: a case-control study · 2026 · Related
  7. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives · Eleonora Nicolò · 2022 · 231 citations · Cited by this paper
  8. Nocturnal enuresis in children with allergic disease: prevalence, phenotype, and ARIA severity analysis · 2026 · Related
  9. Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary Tumours · Achim Fleischmann · 2011 · 186 citations · Cited by this paper
  10. Association between 24-h proteinuria and phenotypic age acceleration in adults with preserved kidney function: a cross-sectional study · 2026 · Related
  11. Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review · Valérie Fonteyne · 2017 · 146 citations · Cited by this paper
  12. Brief review: heart failure as a hemodynamic consequence of high-flow arteriovenous fistulas among end-stage kidney disease patients on hemodialysis · 2026 · Related
  13. Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial · Michiel S. van der Heijden · 2021 · 125 citations · Cited by this paper
  14. Randomized controlled trial comparing deep dermal glanular hyaluronic acid injection versus oral dapoxetine in management of premature ejaculation · 2026 · Related
  15. Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer · Xinan Sheng · 2025 · 95 citations · Cited by this paper
  16. Pediatric bone health in nephrotic syndrome: beyond glucocorticoid exposure and DXA-derived Z-scores · 2026 · Related
  17. HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role · Francesca Sanguedolce · 2023 · 68 citations · Cited by this paper
  18. Serum sclerostin in biopsy-proven glomerulonephritis primarily reflects kidney function: a cross-sectional case–control study · 2026 · Related
  19. Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study · Li Qun Zhou · 2024 · 63 citations · Cited by this paper
  20. Glucagon and GLP-1 in hemodialysis: associations with mortality and nutritional decline · 2026 · Related
  21. A Nationwide, Population Based Analysis of Patients with Organ Confined, Muscle Invasive Bladder Cancer Not Receiving Curative Intent Therapy in Sweden from 1997 to 2014 · Dan-Olle Westergren · 2019 · 49 citations · Cited by this paper
  22. HER2-targeting antibody–drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study · Meiting Chen · 2023 · 47 citations · Cited by this paper
  23. Significance of ERBB2 Overexpression in Therapeutic Resistance and Cancer-Specific Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Selective Bladder-Sparing Approach · Masaharu Inoue · 2014 · 44 citations · Cited by this paper
  24. Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis · Herney Andrés García‐Perdomo · 2018 · 41 citations · Cited by this paper
  25. The Clinical Significance and Prognostic Value of HER2 Expression in Bladder Cancer: A Meta-Analysis and a Bioinformatic Analysis · Kai Gan · 2021 · 40 citations · Cited by this paper
  26. Trimodal therapy vs radical cystectomy in patients with muscle‐invasive bladder cancer: a systematic review and meta‐analysis of comparative studies · Francesco Ditonno · 2024 · 38 citations · Cited by this paper
  27. Bladder preservation therapy for muscle invasive bladder cancer: the past, present and future · Tomokazu Kimura · 2020 · 34 citations · Cited by this paper
  28. Significance of second transurethral resection on patient outcomes in muscle-invasive bladder cancer patients treated with bladder-preserving multimodal therapy · Evren Süer · 2015 · 28 citations · Cited by this paper
  29. Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium · Jiazheng Yu · 2023 · 20 citations · Cited by this paper
  30. Disitamab vedotin vs. gemcitabine-cisplatin regimen with immunotherapy: a comparative analysis of efficacy and safety in muscle-invasive bladder cancer · Chuanao Zhang · 2025 · 9 citations · Cited by this paper
  31. Efficacy and Safety of Disitamab Vedotin Combined with Gemcitabine as Neoadjuvant Therapy in Muscle-invasive Bladder Cancer: An Open-label, Multicenter, Single-arm, Phase 2 Trial · Haijun Huang · 2025 · 7 citations · Cited by this paper
  32. Impact of HER2 Expression on the Prognosis of Muscle-Invasive Bladder Cancer Patients Treated with Bladder-Preservation Comprehensive Therapy · Yatong Chen · 2025 · 4 citations · Cited by this paper
  33. Value of repeat radical transurethral resection for selected patients with muscle‐invasive bladder cancer · Zhuo Li · 2018 · 1 citation · Cited by this paper
  34. Untitled · Cited by this paper
  35. Untitled · Cited by this paper
  36. Untitled · Cited by this paper

Source: OpenAlex (CC0)